OrthoPediatrics (KIDS) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for OrthoPediatrics (NASDAQ: KIDS):

• 10/28/2026 – OrthoPediatrics had its price target raised by Lake Street Capital from $34.00 to $38.00. They now have a “buy” rating on the stock.
• 10/28/2026 – OrthoPediatrics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $30.00 price target on the stock, up from $25.00.
• 10/28/2026 – OrthoPediatrics had its price target raised by Canaccord Genuity Group from $28.00 to $30.00. They now have a “buy” rating on the stock.
• 10/28/2026 – OrthoPediatrics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $35.00 price target on the stock.
• 10/28/2026 – OrthoPediatrics had its price target raised by TD Cowen from $23.00 to $28.00. They now have a “buy” rating on the stock.
• 10/28/2026 – OrthoPediatrics had its price target raised by BTIG Research from $29.00 to $30.00. They now have a “buy” rating on the stock.
• 10/28/2026 – OrthoPediatrics had its price target raised by Stifel Nicolaus from $24.00 to $27.00. They now have a “buy” rating on the stock.
• 10/28/2026 – OrthoPediatrics had its price target raised by Truist Financial from $22.00 to $28.00. They now have a “hold” rating on the stock.
• 10/1/2026 – OrthoPediatrics was upgraded by Truist Financial to “hold”.
• 9/14/2026 – OrthoPediatrics had its “buy” rating reaffirmed by BTIG Research. They now have a $29.00 price target on the stock.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, Director David R. Pelizzon sold 326,700 shares of OrthoPediatrics stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the transaction, the director directly owned 6,536,764 shares of the company’s stock, valued at $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Squadron Capital Llc sold 326,700 shares of OrthoPediatrics stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the transaction, the insider owned 6,536,764 shares in the company, valued at $150,607,042.56. The trade was a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,100,000 shares of company stock worth $46,747,931 in the last three months. 32.50% of the stock is currently owned by company insiders.

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.